Patrick P Gleason
Overview
Explore the profile of Patrick P Gleason including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kenney Jr J, Gleason P
J Manag Care Spec Pharm
. 2025 Jan;
31(2-a Suppl):S20-S24.
PMID: 39888852
No abstract available.
2.
Kenney Jr J, Gleason P
J Manag Care Spec Pharm
. 2025 Jan;
31(1-b Suppl):S20-S24.
PMID: 39873567
No abstract available.
3.
Gleason P, Urick B, Marshall L, Friedlander N, Qiu Y, Leslie R
J Manag Care Spec Pharm
. 2024 May;
30(8):860-867.
PMID: 38717042
Background: In 2014, the US Food and Drug Administration approved the first glucagon-like peptide-1 (GLP-1) receptor agonist product, liraglutide injection, for obesity treatment. Many GLP-1 obesity treatment clinical trials report...
4.
Broderick K, Burke J, Fishman J, Gleason P
J Manag Care Spec Pharm
. 2023 Jul;
29(8):941-951.
PMID: 37523317
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, genetic, chronic, and life-threatening blood disease with an estimated prevalence of 13 per 1,000,000 persons reported in the United States. Available at analysis,...
5.
Marshall L, Espinosa R, Starner C, Gleason P
J Manag Care Spec Pharm
. 2023 Jun;
29(6):599-606.
PMID: 37276039
Cystic fibrosis (CF) is a chronic, progressive genetic disease caused by mutations in the CF transmembrane conductance regulator () gene resulting in a dysfunctional CFTR protein. Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a...
6.
Starner C, Bowen K, Gleason P
J Manag Care Spec Pharm
. 2022 Oct;
28(11):1200-1206.
PMID: 36282927
As new rare-disease drug therapy, gene therapies, and high-priced cancer drugs receive US Food and Drug Administration approval, there is an increasing potential for drug super spender individuals with more...
7.
Smith J, Qiu Y, Lam S, Lockwood C, Pegus C, Gleason P
J Manag Care Spec Pharm
. 2020 Mar;
26(6):766-774.
PMID: 32154745
Background: Pharmacy benefit can be purchased as part of an integrated medical and pharmacy health package-a carve-in model-or purchased separately and administered by an external pharmacy benefit manager-a carve-out model....
8.
Starner C, Gleason P
J Manag Care Spec Pharm
. 2019 Nov;
25(12):1306-1308.
PMID: 31778615
No funding supported the writing of this commentary. The authors are employed by Prime Therapeutics, a pharmacy benefits management company.
9.
Willke R, Chapman R, Seidman J, Schnipper L, Gleason P
Value Health
. 2019 Jun;
22(6S):S7-S11.
PMID: 31200806
No abstract available.
10.
Ollendorf D, Kamal-Bahl S, Gleason P, Schrandt S, McElwee N
Value Health
. 2019 Jun;
22(6S):S29-S31.
PMID: 31200804
No abstract available.